Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab, and Nintedanib in Non-Small Cell Lung Cancer
NCT03377023Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2018
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by Moffitt Cancer Center. Started Feb 2018; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03377023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377023.